As reported by the Economic Times of India, India's largest generic drug maker, Ranbaxy Laboratories, has "voluntarily" suspended all shipments of drug ingredients produced at two of its India-based plants - one in Dewas and one in Toansa - to review processes and controls.
An earlier report from the Economic Times stated that production was halted following a visit from Japanese drug maker Daiichi Sankyo Co., which aquired a controlling share of Ranbaxy in 2008.
This suspension will affect supplies in key markets in Europe and India. All India-based Ranbaxy factories — Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh), Mohali (Punjab) and Toansa (Punjab) — are already barred from exporting drugs to the U.S.
Read the Economic Times release
